Drug Type Bispecific antibody |
Synonyms PSB 202, PSB-202, PSB202 + [3] |
Target |
Action modulators |
Mechanism CD20 modulators(B-lymphocyte antigen CD20 modulators), CD37 modulators(Leukocyte antigen CD37 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Malignant Neoplasm | Phase 1 | United States | 23 Feb 2022 | |
B-Cell Malignant Neoplasm | Phase 1 | China | 23 Feb 2022 | |
B-Cell Malignant Neoplasm | Phase 1 | Australia | 23 Feb 2022 | |
B-cell lymphoma refractory | Phase 1 | United States | 15 Nov 2021 | |
B-cell lymphoma refractory | Phase 1 | China | 15 Nov 2021 | |
B-cell lymphoma refractory | Phase 1 | Australia | 15 Nov 2021 | |
Chronic Lymphocytic Leukemia | Phase 1 | United States | 15 Nov 2021 | |
Chronic Lymphocytic Leukemia | Phase 1 | China | 15 Nov 2021 | |
Chronic Lymphocytic Leukemia | Phase 1 | Australia | 15 Nov 2021 | |
Follicular Lymphoma | Phase 1 | United States | 15 Nov 2021 |
Phase 1 | - | bquorxznsp(hbihraphqb) = wdolyswxho wrypxmgzau (nevaaffkin ) | - | 15 Jun 2022 |